Diamonds in the Rough: The Incredible-but-True Story of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure

Affiliations

¹ Saint Luke's Mid America Heart Institute, Kansas City, MO. University of Missouri-Kansas City. George Institute for Global Health and University of New South Wales, Sydney, Australia.

Editorial

Mikhail Kosiborod. Circulation. 2021.

. 2021 Jan 26;143(4):350-353.

doi: 10.1161/CIRCULATIONAHA.120.052446. Epub 2021 Jan 25.

¹ Saint Luke's Mid America Heart Institute, Kansas City, MO. University of Missouri-Kansas City. George Institute for Global Health and University of New South Wales, Sydney, Australia.

No abstract available

Keywords: Editorials; congestive heart failure; outcomes research; sodium-glucose transporter 2 inhibitor; type 2 diabetes.

Comment on

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CSP, Schnaidt S, Ofstad AP, Brueckmann M, Jamal W, Bocchi EA, Ponikowski P, Perrone SV, Januzzi JL, Verma S, Böhm M, Ferreira JP, Pocock SJ, Zannad F, Packer M. Anker SD, et al. Circulation. 2021 Jan 26;143(4):337-349. doi: 10.1161/CIRCULATIONAHA.120.051824. Epub 2020 Nov 11. Circulation. 2021. PMID: 33175585 Free PMC article.